A retrospective comparative study showed that a panel of four proteins associated with pancreatic cancer significantly improved the detection of the disease, including early stages, compared to a single protein[1]. The test shows potential especially for high-risk patients[1]. The overall accuracy of the test was higher when four proteins were used[1]. The study was published on MedPage Today[1]. The test can detect pancreatic cancer from a drop of blood with a diagnosis success rate of more than 90 percent[1]. It is a non-invasive method based on the analysis of lipids in blood plasma[1]. In 2024, a prospective clinical study began in cooperation with 15 clinical sites in the Czech Republic[1]. The method received a US patent after almost five years of trial[1].